^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LATS2 mutation

    i
    Other names: LATS2, Large Tumor Suppressor Kinase 2, LATS (Large Tumor Suppressor, Drosophila) Homolog 2, Kinase Phosphorylated During Mitosis Protein, Serine/Threonine-Protein Kinase LATS2, Serine/Threonine-Protein Kinase Kpm , Large Tumor Suppressor Homolog 2, Warts-Like Kinase, KPM, LATS, Large Tumor Suppressor, Homolog 2 (Drosophila), LATS, Large Tumor Suppressor, Homolog 2, Serine/Threonine Kinase KPM
    Entrez ID:
    26524
    2ms
    The diagnosis, genetic alternation, and treatment of the primary pleomorphic liposarcoma of the femur in a rare age: Case report and literature review. (PubMed, Heliyon)
    Primary pleomorphic liposarcoma can present as sclerotic and aggressive malignant bone tumors at an early age. Excision, MAP, and MAPI chemotherapy are not enough to treat this tumor.
    Review • Journal
    |
    CREBBP (CREB binding protein) • LATS2 (Large Tumor Suppressor Kinase 2) • SMAD2 (SMAD Family Member 2)
    |
    LATS2 mutation
    2ms
    A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    LATS1 (Large Tumor Suppressor Kinase 1) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    LATS1 mutation • LATS2 mutation
    |
    IAG933
    8ms
    A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Novartis Pharmaceuticals | Trial completion date: May 2025 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    LATS1 (Large Tumor Suppressor Kinase 1) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    LATS1 mutation • LATS2 mutation
    |
    IAG933
    1year
    A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2024 --> May 2025 | Trial primary completion date: Sep 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    LATS1 (Large Tumor Suppressor Kinase 1) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    LATS1 mutation • LATS2 mutation
    |
    IAG933
    over1year
    Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. (PubMed, Front Oncol)
    An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma.
    Review • Journal
    |
    LATS2 (Large Tumor Suppressor Kinase 2)
    |
    LATS2 mutation
    over2years
    Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing. (PubMed, Front Oncol)
    Additionally, differences in the targeted genomic profiles and base substitution patterns were observed between the two groups. These findings comprehensively revealed a molecular characterization of SCRC, which will contribute to the development of personalized therapy and improved clinical management of SCRC patients.
    Journal • Next-generation sequencing • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • GNAQ (G Protein Subunit Alpha Q) • SMAD4 (SMAD family member 4) • CHEK2 (Checkpoint kinase 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • NLRC5 (NLR Family CARD Domain Containing 5) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    TP53 mutation • KRAS mutation • CHEK2 mutation • LATS2 mutation • NLRC5 mutation
    over2years
    A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Novartis Pharmaceuticals | Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    LATS1 (Large Tumor Suppressor Kinase 1) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    LATS1 mutation • LATS2 mutation
    3years
    A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    LATS1 (Large Tumor Suppressor Kinase 1) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    LATS1 mutation • LATS2 mutation
    almost4years
    Next Generation Sequencing analysis suggests varied multistep mutational pathogenesis for Endocrine Mucin Producing Sweat Gland Carcinoma with comments on INSM1 and MUC2 suggesting a conjunctival origin. (PubMed, J Am Acad Dermatol)
    MUC2 positivity suggests conjunctival origin. Multistep pathogenesis involving DNA damage repair and tumor-suppressor pathways may be implicated.
    Journal • IO biomarker • Next-generation sequencing
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • BCL2 (B-cell CLL/lymphoma 2) • AR (Androgen receptor) • RB1 (RB Transcriptional Corepressor 1) • TSC1 (TSC complex subunit 1) • MUC4 (Mucin 4, Cell Surface Associated) • BRD4 (Bromodomain Containing 4) • LATS2 (Large Tumor Suppressor Kinase 2) • MUC2 (Mucin 2)
    |
    TP53 mutation • TSC1 mutation • LATS2 mutation
    |
    MSK-IMPACT